SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin

Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

(2015) Andrea Teague et al.   Therapeutic Advances in Medical Oncology

Therapeutic options for the management of pancreatic cancer

(2014) Maria L Rossi   WORLD JOURNAL OF GASTROENTEROLOGY

Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection

(2014) Andrew E Becker   WORLD JOURNAL OF GASTROENTEROLOGY

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

(2013) M-C Chen et al.   Cell Death & Disease

Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach

(2012) Falko Lange   WORLD JOURNAL OF GASTROENTEROLOGY

Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer

(2011) Ali Aghdassi et al.   GUT

Misregulated E-Cadherin Expression Associated with an Aggressive Brain Tumor Phenotype

(2010) Laura J. Lewis-Tuffin et al.   PLoS One

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

(2008) P. C. Black et al.   CLINICAL CANCER RESEARCH